A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

Seminars in Immunology

Volumn 26, Issue 1, 2014, Pages 88-96

  Tanaka, Toshio ^a,b   Narazaki, Masashi ^a   Ogata, Atsushi ^a,b   Kishimoto, Tadamitsu ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Autoimmunity; IL 6; Inflammation; Tocilizumab

Indexed keywords

ADALIMUMAB; ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; FIBRONECTIN; HAPTOGLOBIN; INTERLEUKIN 6; METHOTREXATE; SERUM AMYLOID A; TOCILIZUMAB; TRANSFERRIN;

ADULT ONSET STILL DISEASE; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; CELL POPULATION; CYTOKINE RELEASE SYNDROME; DRUG EFFICACY; GIANT CELL ARTERITIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LARGE VESSEL VASCULITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION; VASCULITIS;

AUTOIMMUNITY; IL-6; INFLAMMATION; TOCILIZUMAB;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84896495791     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.01.009     Document Type: Review

References (95)

1. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
2. Kishimoto T. The biology of interleukin-6. Blood 1989, 74:1-10.
3. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Acad Natl Sci U S A 1989, 86:7547-7551.
4. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
5. Chihara N., Aranami T., Sato W., Miyazaki Y., Miyake S., Okamoto T., et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011, 108:3701-3706.
6. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
7. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
8. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010, 40:1830-1835.
9. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008, 58:3710-3719.
10. Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi Y., Nomura S., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008, 105:9041-9046.
11. Haruta H., Ohguro N., Fujimoto M., Hohki S., Terabe F., Serada S., et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011, 52:3264-3271.
12. Ma C.S., Deenick E.K., Batten M., Tangye S.G. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012, 209:1241-1253.
13. Okada M., Kitahara M., Kishimoto S., Matsuda T., Hirano T., Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988, 141:1543-1549.
14. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
15. Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959-3964.
16. Tanaka T., Hagihara K., Hishitani Y., Ogata A. Tocilizumab for the treatment of AA amyloidosis. Amyloidosis - An Insight to Disease of Systems and Novel Therapies 2011, 155-170. INTECH Open Access Publisher, Croatia. I.A. Guvenc (Ed.).
17. Gillmore J.D., Lovat L.B., Persey M.R., Pepys M.B., Hawkins P.N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
18. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
19. Liuzzi J.P., Lichten L.A., Rivera S., Blanchard R.K., Aydemir T.B., Knutson M.D., et al. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A 2005, 102:6843-6848.
20. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990, 11:443-449.
21. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
22. Hashizume M., Hayakawa N., Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008, 47:1635-1640.
23. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
24. Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
25. Grossman R.M., Krueger J., Yourish D., Granelli-Piperno A., Murphy D.P., May L.T., et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989, 86:6367-6371.
26. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991, 97:686-692.
27. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992, 258:593-597.
28. Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B., et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988, 241:825-828.
29. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
30. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82:1120-1126.
31. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
32. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993, 260:1808-1810.
33. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011, 21:3375-3383.
34. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. Int J Biol Sci 2012, 8:1237-1247.
35. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
36. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell 1994, 76:253-262.
37. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
38. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment sites of gp130. J Biol Chem 2000, 275:12848-12856.
39. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
40. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
41. Tanaka T., Narazaki M., Masuda K., Kishimoto T. Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. Inflamm Regeneration 2013, 33:54-65.
42. Akira S., Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992, 127:25-50.
43. Anderson P. Post-transcriptional control of cytokine production. Nat Immunol 2008, 9:353-359.
44. Chen C.Y., Shyu A.B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995, 20:465-470.
45. Matsushita K., Takeuchi O., Standley D.M., Kumagai Y., Kawagoe T., Miyake T., et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009, 458:1185-1190.
46. Iwasaki H., Takeuchi O., Teraguchi S., Matsushita K., Uehata T., Kuniyoshi K., et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol 2011, 12:1167-1175.
47. Masuda K., Ripley B., Nishimura R., Mino T., Takeuchi O., Shioi G., et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci U S A 2013, 110:9409-9414.
48. Hirano T., Taga T., Yasukawa K., Nakajima K., Nakano N., Takatsuki F., et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A 1987, 84:228-231.
49. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988, 18:1797-1801.
50. Yoshizaki K., Matsuda T., Nishimoto N., Kuritani T., Taeho L., Aozasa K., et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74:1360-1367.
51. Katsume A., Saito H., Yamada Y., Yorozu K., Ueda O., Akamatsu K., et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002, 20:304-311.
52. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998, 187:461-468.
53. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998, 95:8222-8226.
54. Mihara M., Takagi N., Takeda Y., Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397-402.
55. Yoshizaki A., Yanaba K., Ogawa A., Asano Y., Kadono T., Sato S. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011, 63:3575-3585.
56. Kitaba S., Murota H., Terao M., Azukizawa H., Terabe F., Shima Y., et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012, 180:165-176.
57. Okiyama N., Sugihara T., Iwakura Y., Yokozeki H., Miyasaka N., Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009, 60:2505-2512.
58. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005, 23:1-21.
59. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52:199-219.
60. Sato K., Tsuchiya M., Saldanha J., Koishihara Y., Ohsugi Y., Kishimoto T., et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993, 53:851-856.
61. Tanaka T., Ogata A., Narazaki M. Tocilizumab: an updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases. Clin Med Insights Ther 2013, 5:33-52.
62. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
63. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395.
64. Nishimoto N., Sasai M., Shima Y., Nakagawa M., Matsumoto T., Shirai T., et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56-61.
65. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-2632.
66. Mclnnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
67. Ogata A., Hirano T., Hishitani Y., Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2012, 5:27-42.
68. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
69. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12-19.
70. Dougados M., Kissel K., Sheeran T., Tak P.P., Conaghan P.G., Mola E.M., et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013, 72:43-50.
71. Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013, 381:1541-1550.
72. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013, [Epub ahead of print].
73. Burmester G.R., Rubbert-Roth A., Cantagrel A., Hall S., Leszczynski P., Feldman D., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014, 73:69-74.
74. Ogata A., Tanimura K., Sugimoto T., Inoue H., Urata Y., Matsubara T., et al. A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care Res (Hoboken) 2013, [Epub ahead of print].
75. Yokota S., Tanaka T., Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis 2012, 4:387-397.
76. Sandborg C., Mellins E.D. A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2439-2440.
77. Brandt S.J., Bodine D.M., Dunbar C.E., Nienhuis A.W. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990, 86:592-599.
78. Beck J.T., Hsu S.M., Wijdenes J., Bataille R., Klein B., Vesole D., et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994, 330:602-605.
79. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
80. Shima Y., Kuwahara Y., Murota H., Kitaba S., Kawai M., Hirano T., et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010, 49:2408-2412.
81. Unizony S., Stone J.H., Stone J.R. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013, 25:3-9.
82. Kermani T.A., Warrington K.J. Polymyalgia rheumatica. Lancet 2013, 381:63-72.
83. Nishida S., Hagihara K., Shima Y., Kawai M., Kuwahara Y., Arimitsu J., et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009, 68:1235-1236.
84. Sahraian M.A., Radue E.W., Minagar A. Neuromyelitis optica: clinical manifestations and neuroimaging features. Neurol Clin 2013, 31:139-152.
85. Araki M., Aranami T., Matsuoka T., Nakamura M., Miyake S., Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013, 23:827-831.
86. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008, 22:773-792.
87. Imai Y., Kuba K., Neely G.G., Yaghubian-Malhami R., Perkmann T., van Loo G., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008, 133:235-249.
88. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
89. Teachey D.T., Rheingold S.R., Maude S.L., Zugmaier G., Barrett D.M., Seif A.E., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013, 121:5154-5157.
90. Tanaka T., Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012, 8:1227-1236.
91. Tanaka T., Ogata A., Kishimoto T. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol Curr Res 2013, S4-002.
92. Garnero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62:33-43.
93. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
94. Pesce B., Soto L., Sabugo F., Wurmann P., Cuchacovich M., Lopez M.N., et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 2013, 171:237-242.
95. Carbone G., Wilson A., Diehl S.A., Bunn J., Cooper S.M., Rincon M. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 2013, 9:279-288.